Ambu stock trades steady as single-use endoscopy drives growth

Ambu A/S (ISIN DK0060946788) stock is supported by ongoing growth in single-use endoscopy, while recent earnings show the impact of investments on profitability in fiscal 2023 and the first half of fiscal 2024. The Danish medtech company, traded on Nasdaq Copenhagen, continues to expand its portfolio and commercial footprint in minimally invasive procedures.

Revenue trends and earnings pressure

Ambu A/S reported full-year revenue of DKK 4,610 million in fiscal 2023, reflecting the scale of its global business in single-use endoscopy, anesthesia, and patient monitoring. According to the company’s annual reporting for fiscal 2023, this revenue base is underpinned by a broad hospital customer network in North America, Europe, and Asia-Pacific, along with long-standing anesthesia and airway management products that complement newer endoscopy offerings.

Within that fiscal 2023 performance, operating profit (EBIT) came under pressure as Ambu continued to invest in commercial expansion and product development. The company’s stated strategy emphasizes long-term growth in single-use endoscopy, and the fiscal 2023 figures show how higher costs in sales, marketing, and R&D tightened margins compared with earlier years. The combination of rising revenue with lower operating profit highlights a transition phase in which Ambu balances earnings with future growth potential.

The development continued into fiscal 2024, where interim results for the first half of the year pointed to ongoing revenue momentum but a mixed earnings profile. Ambu has indicated that single-use endoscopy remains the key driver of top-line expansion, while legacy anesthesia and patient monitoring products provide a stable base. At the same time, the company’s investment program weighs on profitability, particularly in regions where sales teams and clinical support for single-use devices are being expanded.

Single-use endoscopy revenue up double digits

Ambu’s single-use endoscopy franchise has grown into a central pillar of its business, with double-digit revenue growth in recent periods as hospitals adopt disposable scopes to reduce infection risk and workflow complexity. In fiscal 2023, growth in single-use endoscopy revenue outpaced the company average, supporting an increase in total sales despite pricing and reimbursement pressures in some markets. This segment includes Bronchoscopy, ENT, and Urology devices that are used once per procedure and then discarded, avoiding the need for reprocessing.

The company’s reporting shows that single-use endoscopy revenue increased at a rate that compares favorably with the broader medtech market, which generally grows at mid-single-digit to low-double-digit rates annually. Ambu’s faster growth in this area reflects its early-mover position and strong clinical evidence supporting the safety and efficiency benefits of disposable scopes. For investors, the key comparison is between this double-digit expansion in endoscopy revenue and more modest growth in traditional anesthesia products, which helps explain the strategic focus of management.

Ambu has also highlighted geographic differences in growth, with North America contributing a significant share of single-use endoscopy revenue. The company’s data indicate that penetration of disposable scopes in US hospitals is still in the early to mid stages, leaving room for further adoption. Meanwhile, European and Asia-Pacific markets are progressing at different speeds depending on regulatory frameworks and reimbursement, but collectively they add diversification to the growth profile.

Margin dynamics and investment cycle

While single-use endoscopy revenue grows at double-digit rates, Ambu’s margin dynamics show the cost of sustaining that growth. In fiscal 2023, gross margin and EBIT margin were influenced by the need to expand manufacturing capacity, support innovation, and provide field-based clinical education. The company’s margin levels remain below the peak achieved before its current investment cycle, underscoring the trade-off between near-term earnings and long-term market share gains.

Ambu’s commentary around its results emphasizes a disciplined approach to spending, but acknowledges that building a leading position in single-use endoscopy requires continued investment. For example, the company has added sales representatives and clinical specialists in key markets, which increases selling expenses but also accelerates adoption. In parallel, R&D spending supports pipeline development in new procedural areas where single-use scopes may be introduced, such as gastroenterology.

From an investor perspective, the quantified comparison between revenue growth and margin pressure is central. Ambu’s double-digit revenue expansion in single-use endoscopy contrasts with tighter EBIT margins, indicating that operating leverage has not yet fully materialized. Over time, higher sales volumes and manufacturing efficiency could improve margins, but the current data show that the investment phase is still underway.

Balance sheet and cash flow considerations

Ambu’s balance sheet provides context for its investment capabilities. The company reports a level of net interest-bearing debt that is manageable relative to its revenue base, with leverage metrics monitored to maintain financial flexibility. Cash flow from operations in fiscal 2023 and the first half of fiscal 2024 reflects both the profitability impact of investments and working-capital movements related to inventory and receivables.

Capital expenditure has been directed toward manufacturing capacity for single-use endoscopy, including production lines designed to handle high volumes of disposable devices. This capex adds to near-term cash outflows but supports future growth potential. Ambu’s management has indicated that the company aims to balance investment needs with maintaining a sound financial position, which matters for its ability to fund innovation and commercial expansion without stressing the balance sheet.

Dividend policy is also part of the financial picture, though payout levels depend on earnings and cash flow. In periods when profitability is under pressure due to investments, dividend decisions can signal how management prioritizes shareholder returns versus reinvestment. Ambu’s historical approach has been to adjust dividends according to financial performance, and investors watch these choices as an additional indicator of confidence in the growth strategy.

Single-use endoscopy product line

Ambu’s single-use endoscopy portfolio includes disposable bronchoscopes, rhinolaryngoscopes, and urology scopes that are used in ICU, operating-room, and outpatient settings. These devices are designed to provide high-quality imaging and maneuverability, while eliminating the need for reprocessing that reusable scopes require. Hospitals that adopt single-use scopes can reduce the logistical complexity of cleaning and sterilization, which may lower the risk of cross-contamination and infections.

In addition to clinical benefits, single-use endoscopy supports more flexible scheduling because scopes are readily available for procedures without waiting for cleaning cycles. Ambu’s revenue growth in this segment indicates that customers value these operational advantages, even as they assess cost implications versus reusable alternatives. The company’s product development aims to extend single-use technology into new anatomical areas and procedural types, potentially broadening the addressable market over the coming years.

Ambu stock and market context

Ambu stock on Nasdaq Copenhagen reflects the balance between growth in single-use endoscopy and the earnings impact of continued investment. The company’s market capitalization, expressed in Danish kroner, corresponds to investor expectations around future revenue expansion and margin recovery. Price levels on the exchange move in response to quarterly and annual results, guidance updates, and broader medtech sector sentiment.

For investors following Ambu stock, the core quantitative narrative is clear: double-digit revenue growth in single-use endoscopy, stable but slower-growing legacy product lines, and margins tempered by investment in capacity and market development. As adoption of disposable scopes progresses and scale efficiencies emerge, the relationship between revenue and profit will remain central to how the stock is valued.